---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-016083"
form_type: "8-K"
ticker: "TXMD"
cik: "0000025743"
company_name: "TherapeuticsMD, Inc."
filed_at: "2022-04-27T23:59:59+00:00"
generated_at: "2026-06-26T04:14:41.830670+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# TherapeuticsMD announces 1-for-50 reverse stock split to regain Nasdaq bid price compliance

## Summary
- Board approves 1-for-50 reverse stock split to cure Nasdaq minimum bid price non-compliance.
- Effective May 6, 2022 at 5:00 p.m. ET; post-split trading on Nasdaq under "TXMD" begins May 9, 2022.
- No stockholder vote required; fractional shares rounded up to nearest whole share.
- Nasdaq granted extension to June 1, 2022 to regain compliance with $1.00 bid price.
- Authorized shares reduced from 600 million to 12 million; authorized reduction matches split.

## SEC filing metadata
- accession: 0001564590-22-016083
- form_type: 8-K
- ticker: TXMD
- cik: 0000025743
- company_name: TherapeuticsMD, Inc.
- filed_at: 2022-04-27T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/25743/000156459022016083/0001564590-22-016083-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/25743/000156459022016083/txmd-8k_20220427.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-016083
- JSON: https://secwatch.observer/filing/0001564590-22-016083.json
- Plain text: https://secwatch.observer/filing/0001564590-22-016083.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.